FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076643424> ?p ?o ?g. }

• W2076643424 endingPage "1330" @default.
• W2076643424 startingPage "1321" @default.
• W2076643424 abstract "Purpose The effects of age and comorbidity on treatment and outcomes for patients with limited stage small-cell lung cancer (L-SCLC) are unclear. This study analyzes relapse and survival in a community-based population with L-SCLC according to age and comorbidity. Methods A retrospective review was performed on 174 patients with L-SCLC referred to the British Columbia Cancer Agency, Vancouver Island Centre, between January 1991 and December 1999. Patient and treatment characteristics, disease response, relapse, and survival were compared among three age cohorts: <65 years (n = 55, 32%), 65–74 years (n = 76, 44%), and ≥75 years (n = 43, 25%); and according to Charlson comorbidity scores 0, 1, and ≥2. Multivariate analysis was performed to identify independent prognostic factors associated with treatment response and survival. Results Patient factors that significantly differed with age were functional status classified by Eastern Cooperative Oncology Group performance status and number of comorbidities. Increasing age was significantly associated with fewer diagnostic scans. Combined modality chemoradiotherapy (CRT) was given in 86%, 66%, and 40% of patients ages <65, 65–74, and ≥75 years, respectively, (p <0.0001). Thoracic irradiation use was comparable among the age cohorts (p >0.05), but chemotherapy use varied significantly with less intensive regimens, fewer cycles, and lower total doses with advancing age (p <0.05). Prophylactic cranial irradiation (PCI) was used in 41 patients, only 3 of whom were age >70 years. Overall response rates to primary treatment significantly decreased with advancing age: 91%, 79%, and 74% in patients ages <65, 65–74, and ≥75 years, respectively (p = 0.014). Treatment toxicity and relapse patterns were similar across the age cohorts. Overall 2-year survival rates were significantly lower with advancing age: 37%, 22%, and 19% (p = 0.003), with corresponding median survivals of 17, 12, and 7 months among patients ages <65, 65–74, and ≥75 years, respectively. On multivariate analysis, age and Charlson comorbidity scores were not significantly associated with treatment response and survival. Independent prognostic factors favorably associated with survival were good performance status, normal lactate dehydrogenase, absence of pleural effusion, and ≥four cycles of chemotherapy. Conclusion Increasing age was associated with decreased performance status and increased comorbidity. Older patients with L-SCLC were less likely to be treated with CRT, intensive chemotherapy, and PCI. Treatment response and survival rates were lower with advancing age, but this may be attributed to poor performance status and suboptimal treatment rather than age." @default.
• W2076643424 created "2016-06-24" @default.
• W2076643424 creator A5017803772 @default.
• W2076643424 creator A5020713848 @default.
• W2076643424 creator A5041062561 @default.
• W2076643424 creator A5044433786 @default.
• W2076643424 creator A5077900568 @default.
• W2076643424 creator A5085426335 @default.
• W2076643424 creator A5090903637 @default.
• W2076643424 creator A5091101559 @default.
• W2076643424 date "2003-04-01" @default.
• W2076643424 modified "2023-09-23" @default.
• W2076643424 title "Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis" @default.
• W2076643424 cites W1851872955 @default.
• W2076643424 cites W1885320430 @default.
• W2076643424 cites W1895855332 @default.
• W2076643424 cites W1900867937 @default.
• W2076643424 cites W1905406155 @default.
• W2076643424 cites W1991272247 @default.
• W2076643424 cites W1999960570 @default.
• W2076643424 cites W2000445173 @default.
• W2076643424 cites W2037930008 @default.
• W2076643424 cites W2044746763 @default.
• W2076643424 cites W2054121888 @default.
• W2076643424 cites W2062668422 @default.
• W2076643424 cites W2064003771 @default.
• W2076643424 cites W2067965045 @default.
• W2076643424 cites W2073153700 @default.
• W2076643424 cites W2076668534 @default.
• W2076643424 cites W2082851735 @default.
• W2076643424 cites W2134855461 @default.
• W2076643424 cites W2156836360 @default.
• W2076643424 cites W2164306710 @default.
• W2076643424 cites W2180933151 @default.
• W2076643424 cites W2323020638 @default.
• W2076643424 cites W2331849216 @default.
• W2076643424 cites W2339444986 @default.
• W2076643424 cites W2341745217 @default.
• W2076643424 cites W4320300890 @default.
• W2076643424 doi "https://doi.org/10.1016/s0360-3016(02)04576-5" @default.
• W2076643424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12654444" @default.
• W2076643424 hasPublicationYear "2003" @default.
• W2076643424 type Work @default.
• W2076643424 sameAs 2076643424 @default.
• W2076643424 citedByCount "124" @default.
• W2076643424 countsByYear W20766434242012 @default.
• W2076643424 countsByYear W20766434242013 @default.
• W2076643424 countsByYear W20766434242014 @default.
• W2076643424 countsByYear W20766434242015 @default.
• W2076643424 countsByYear W20766434242016 @default.
• W2076643424 countsByYear W20766434242017 @default.
• W2076643424 countsByYear W20766434242018 @default.
• W2076643424 countsByYear W20766434242019 @default.
• W2076643424 countsByYear W20766434242020 @default.
• W2076643424 countsByYear W20766434242021 @default.
• W2076643424 countsByYear W20766434242022 @default.
• W2076643424 countsByYear W20766434242023 @default.
• W2076643424 crossrefType "journal-article" @default.
• W2076643424 hasAuthorship W2076643424A5017803772 @default.
• W2076643424 hasAuthorship W2076643424A5020713848 @default.
• W2076643424 hasAuthorship W2076643424A5041062561 @default.
• W2076643424 hasAuthorship W2076643424A5044433786 @default.
• W2076643424 hasAuthorship W2076643424A5077900568 @default.
• W2076643424 hasAuthorship W2076643424A5085426335 @default.
• W2076643424 hasAuthorship W2076643424A5090903637 @default.
• W2076643424 hasAuthorship W2076643424A5091101559 @default.
• W2076643424 hasConcept C121608353 @default.
• W2076643424 hasConcept C126322002 @default.
• W2076643424 hasConcept C143998085 @default.
• W2076643424 hasConcept C146357865 @default.
• W2076643424 hasConcept C151730666 @default.
• W2076643424 hasConcept C167135981 @default.
• W2076643424 hasConcept C2776256026 @default.
• W2076643424 hasConcept C2778424827 @default.
• W2076643424 hasConcept C2779159551 @default.
• W2076643424 hasConcept C2908647359 @default.
• W2076643424 hasConcept C38180746 @default.
• W2076643424 hasConcept C509974204 @default.
• W2076643424 hasConcept C71924100 @default.
• W2076643424 hasConcept C86803240 @default.
• W2076643424 hasConcept C99454951 @default.
• W2076643424 hasConceptScore W2076643424C121608353 @default.
• W2076643424 hasConceptScore W2076643424C126322002 @default.
• W2076643424 hasConceptScore W2076643424C143998085 @default.
• W2076643424 hasConceptScore W2076643424C146357865 @default.
• W2076643424 hasConceptScore W2076643424C151730666 @default.
• W2076643424 hasConceptScore W2076643424C167135981 @default.
• W2076643424 hasConceptScore W2076643424C2776256026 @default.
• W2076643424 hasConceptScore W2076643424C2778424827 @default.
• W2076643424 hasConceptScore W2076643424C2779159551 @default.
• W2076643424 hasConceptScore W2076643424C2908647359 @default.
• W2076643424 hasConceptScore W2076643424C38180746 @default.
• W2076643424 hasConceptScore W2076643424C509974204 @default.
• W2076643424 hasConceptScore W2076643424C71924100 @default.
• W2076643424 hasConceptScore W2076643424C86803240 @default.
• W2076643424 hasConceptScore W2076643424C99454951 @default.
• W2076643424 hasIssue "5" @default.
• W2076643424 hasLocation W20766434241 @default.

• next